Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation (Take Rate) of a Cell-Cultured Smallpox Vaccine (CCSV) Compared to a Calf Lymph Vaccine (Dryvax®)

NCT00042094 is registered in ClinicalTrials.gov with DynPort Vaccine Company LLC, A GDIT Company as lead sponsor.

NCT NCT00042094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00042094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation (Take Rate) of a Cell-Cultured Smallpox Vaccine (CCSV) Compared to a Calf Lymph Vaccine (Dryvax®)
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2002
Completion date
March 31, 2003
Enrollment
350
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

smallpox